• Product NameBelinostat (PXD101)
• Brief DescriptionInhibitors
• Purification99.96%
• Biological ActivityBelinostat is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.
• Target NameHDAC inhibitor
• CAS No. 414864-00-9
• Calculated MW 318.35
• Formulation C15H14N2O4S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Other
  SMILES:C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO
  Pathways:Chromatin/Epigenetic; DNA Damage/DNA Repair; NF-κb
  Receptor:HDAC
  Boling pt:
  Melting pt:
  Solubility:DMSO: 64 mg/mL (201.03 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Savickiene J, et al. AntiY Drugs. 2014 Sep;25(8):938-49.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting